Abstract
Genomic testing and targeted use of non-steroidal anti-inflammatory drugs (NSAIDs) may mitigate cancer recurrence risks. This study examines colorectal cancer (CRC) survivors’ interest and receptivity to these strategies. Patients diagnosed with stage I-III CRC in 2004–2012 were recruited through the New Mexico Cancer Registry to complete a cancer survivorship experiences survey. We assessed interest in genomic testing, daily aspirin (ASA) and NSAID use, and receptivity to future daily ASA/NSAIDs. Descriptive statistics and multivariable logistic regression models estimated factors associated with genomic testing interest. Receptivity to future ASA/NSAIDs use was estimated for non-users of ASA/NSAIDs. Among CRC survivors (n = 273), 83% endorsed interest in genomic testing, 25% were ASA users and 47% ASA/NSAIDs users. In our final model, genomic testing interest was associated with being uncoupled [OR = 4.11; 95% CI = 1.49–11.35], low income [OR = 0.35, 95% CI: 0.14–0.88], smoking history [OR = 0.35, 95% CI: 0.14–0.90], low [OR: 0.33, 95% CI: 0.07–1.43] and moderate [OR: 0.26, 95% CI: 0.11–0.61] health literacy, and personal CRC risk worry [OR: 2.86, 95% CI: 1.63–5.02, p = 0.0002]. In our final model, ASA use was associated with age [OR: 1.05, 95% CI: 1.01–1.10] and cardiovascular disease history [OR: 2.42, 95% CI: 1.23–4.73, p = 0.010]. Among non-users ASA/NSAIDs, 83% reported receptivity to ASA/NSAIDs to reduce cancer risks, and no significant correlates were identified. The majority of survivors’ expressed genomic testing interest and endorsed receptivity toward ASA/NSAIDs use for cancer risk management. Further research to optimize ASA/NSAIDs use guided by genomic testing is warranted.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM et al (2019) Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 69(5):363–385. https://doi.org/10.3322/caac.21565
Relling MV, Evans WE (2015) Pharmacogenomics in the clinic. Nature 526(7573):343–350
Zafar SN, Hu CY, Snyder RA, Cuddy A, You YN, Lowenstein LM et al (2020) Predicting risk of recurrence after colorectal cancer surgery in the United States: an analysis of a special Commission on Cancer National Study Ann SurgOncol. https://doi.org/10.1245/s10434-020-08238-7
Fisher A, Beeken RJ, Heinrich M, Williams K, Wardle J (2016) Health behaviours and fear of cancer recurrence in 10 969 colorectal cancer (CRC) patients. Psychooncology 25(12):1434–1440. https://doi.org/10.1002/pon.4076
Custers JAE, Gielissen MFM, Janssen SHV, de Wilt JHW, Prins JB (2016) Fear of cancer recurrence in colorectal cancer survivors. Support Care Cancer 24(2):555–562. https://doi.org/10.1007/s00520-015-2808-4
Simard S, Thewes B, Humphris G, Dixon M, Hayden C, Mireskandari S et al (2013) Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. J Cancer Surviv 7(3):300–322. https://doi.org/10.1007/s11764-013-0272-z
N Bartley G Davies P Butow CE Napier T Schlub ML Ballinger et al 2021 Fear of cancer recurrence in patients undergoing germline genome sequencing Support Care Cancer https://doi.org/10.1007/s00520-021-06311-9
Engstrom PF, Arnoletti JP, Benson AB 3rd, Chen YJ, Choti MA, Cooper HS et al (2009) NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw 7(8):778–831. https://doi.org/10.6004/jnccn.2009.0056
Abrha A, Shukla ND, Hodan R, Longacre T, Raghavan S, Pritchard CC et al (2020) Universal screening of gastrointestinal malignancies for mismatch repair deficiency at Stanford. JNCI Cancer Spectr 4(5):pkaa054. https://doi.org/10.1093/jncics/pkaa054
Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW et al (1998) A National Cancer Institute Workshop on Microsatellite Instability for Cancer Detection and Familial Predisposition: Development of International Criteria for the Determination of Microsatellite Instability in Colorectal Cancer. Can Res 58(22):5248–5257
Jung WB, Kim CW, Yoon YS, Park IJ, Lim SB, Yu CS et al (2016) Observational study: Familial relevance and oncological significance of revised bethesda guidelines in colorectal patients that have undergone curative resection. Medicine (baltimore) 95(6):e2723. https://doi.org/10.1097/md.0000000000002723
Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM et al (1997) A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 89(23):1758–1762. https://doi.org/10.1093/jnci/89.23.1758
Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J et al (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96(4):261–268. https://doi.org/10.1093/jnci/djh034
Stoffel E, Mukherjee B, Raymond VM, Tayob N, Kastrinos F, Sparr J et al (2009) Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 137(5):1621–1627. https://doi.org/10.1053/j.gastro.2009.07.039
Cross DS, Rahm AK, Kauffman TL, Webster J, Le AQ, Spencer Feigelson H et al (2013) Underutilization of Lynch syndrome screening in a multisite study of patients with colorectal cancer. Genet Med 15(12):933–940. https://doi.org/10.1038/gim.2013.43
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genetics in Medicine 11(1):35–41. https://doi.org/10.1097/GIM.0b013e31818fa2ff
Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN (2009) EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 11(1):42–65. https://doi.org/10.1097/GIM.0b013e31818fa2db
Zhang Z, Chen F, Shang L (2018) Advances in antitumor effects of NSAIDs. Cancer Manag Res 10:4631–4640. https://doi.org/10.2147/CMAR.S175212
Umezawa S, Higurashi T, Komiya Y, Arimoto J, Horita N, Kaneko T et al (2019) Chemoprevention of colorectal cancer: Past, present, and future. Cancer Sci 110(10):3018–3026. https://doi.org/10.1111/cas.14149
Chan AT (2016) Metformin for cancer prevention: a reason for optimism. Lancet Oncol 17(4):407–409. https://doi.org/10.1016/s1470-2045(16)00006-1
Bibbins-Domingo K (2016) Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 164(12):836–45. https://doi.org/10.7326/m16-0577
Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA et al (2012) Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (phila) 5(2):164–178. https://doi.org/10.1158/1940-6207.Capr-11-0391
Garcia-Albeniz X, Chan AT (2011) Aspirin for the prevention of colorectal cancer. Best Pract Res Clin Gastroenterol 25(4–5):461–472. https://doi.org/10.1016/j.bpg.2011.10.015
Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP et al (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376(9754):1741–1750. https://doi.org/10.1016/s0140-6736(10)61543-7
Ishikawa H, Mutoh M, Suzuki S, Tokudome S, Saida Y, Abe T et al (2014) The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. Gut 63(11):1755–1759. https://doi.org/10.1136/gutjnl-2013-305827
Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R et al (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348(10):891–899. https://doi.org/10.1056/NEJMoa021735
Benamouzig R, Uzzan B, Deyra J, Martin A, Girard B, Little J et al (2012) Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial. Gut 61(2):255–261. https://doi.org/10.1136/gutjnl-2011-300113
Logan RF, Grainge MJ, Shepherd VC, Armitage NC, Muir KR (2008) Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 134(1):29–38. https://doi.org/10.1053/j.gastro.2007.10.014
Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R et al (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348(10):883–890. https://doi.org/10.1056/NEJMoa021633
van Oijen MG, Laheij RJ, Koetsier M, de Kleine E, Te Morsche RH, van Kerkhoven LA et al (2006) Effect of a specific cyclooxygenase-gene polymorphism (A-842G/C50T) on the occurrence of peptic ulcer hemorrhage. Dig Dis Sci 51(12):2348–2352. https://doi.org/10.1007/s10620-006-9475-8
Zumwalt TJ, Wodarz D, Komarova NL, Toden S, Turner J, Cardenas J et al (2017) Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells. Cancer Prev Res (phila) 10(3):208–218. https://doi.org/10.1158/1940-6207.Capr-16-0175
El-Shami K, Oeffinger KC, Erb NL, Willis A, Bretsch JK, Pratt-Chapman ML et al (2015) American Cancer Society Colorectal Cancer Survivorship Care Guidelines. CA Cancer J Clin 65(6):427–455. https://doi.org/10.3322/caac.21286
Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version, et al (2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 33(13):1635–701. https://doi.org/10.1093/eurheartj/ehs092
Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P et al (2012) Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e637S – e668. https://doi.org/10.1378/chest.11-2306
Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S et al (2011) Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42(2):517–584. https://doi.org/10.1161/STR.0b013e3181fcb238
Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150(6):396–404. https://doi.org/10.7326/0003-4819-150-6-200903170-00008.
Weaver KE, Foraker RE, Alfano CM, Rowland JH, Arora NK, Bellizzi KM et al (2013) Cardiovascular risk factors among long-term survivors of breast, prostate, colorectal, and gynecologic cancers: a gap in survivorship care? J Cancer Surviv 7(2):253–261. https://doi.org/10.1007/s11764-013-0267-9
McBride CM, Birmingham WC, Kinney AY (2015) Health psychology and translational genomic research: bringing innovation to cancer-related behavioral interventions. Am Psychol 70(2):91–104. https://doi.org/10.1037/a0036568
Cuffe S, Hon H, Qiu X, Tobros K, Wong CK, De Souza B et al (2014) Cancer patients acceptance, understanding, and willingness-to-pay for pharmacogenomic testing. Pharmacogenet Genomics 24(7):348–355. https://doi.org/10.1097/fpc.0000000000000061
Hunter JE, Zepp JM, Gilmore MJ, Davis JV, Esterberg EJ, Muessig KR et al (2015) Universal tumor screening for Lynch syndrome: Assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers. Cancer 121(18):3281–3289. https://doi.org/10.1002/cncr.29470
Hamilton JG, Shuk E, Genoff MC, Rodríguez VM, Hay JL, Offit K et al (2017) Interest and Attitudes of Patients With Advanced Cancer With Regard to Secondary Germline Findings From Tumor Genomic Profiling. J Oncol Practice 13(7):e590–e601. https://doi.org/10.1200/jop.2016.020057
Stefanidis D, Pollock BH, Miranda J, Wong A, Sharkey FE, Rousseau DL et al (2006) Colorectal cancer in Hispanics: a population at risk for earlier onset, advanced disease, and decreased survival. Am J Clin Oncol 29(2):123–126. https://doi.org/10.1097/01.coc.0000199918.31226.f8
Miller KD, Goding Sauer A, Ortiz AP, Fedewa SA, Pinheiro PS, Tortolero-Luna G et al (2018) Cancer Statistics for Hispanics/Latinos, 2018. CA Cancer J Clin 68(6):425–445. https://doi.org/10.3322/caac.21494
Muller C, Lee SM, Barge W, Siddique SM, Berera S, Wideroff G et al (2018) Low Referral Rate for Genetic Testing in Racially and Ethnically Diverse Patients Despite Universal Colorectal Cancer Screening. Clin Gastroenterol Hepatol 16(12):1911–8.e2. https://doi.org/10.1016/j.cgh.2018.08.038
Wang SC, Yeu Y, Hammer STG, Xiao S, Zhu M, Hong C et al (2020) Hispanic/Latino Patients with Gastric Adenocarcinoma Have Distinct Molecular Profiles Including a High Rate of Germline CDH1 Variants. Can Res 80(11):2114–2124. https://doi.org/10.1158/0008-5472.Can-19-2918
U.S. Census (2019) Quick facts: Population estimates
U.S. Department of Health and Human Services. (2015) Poverty Guidelines (updated periodically in the Federal Register by the U.S. Department of Health and Human Services under the authority of 42 U.S.C 9902(2). In: Evaluation OotASfPa, editor
World Population Review. (2021) Poverty rate by state. https://worldpopulationreview.com/state-rankings/poverty-rate-by-state
McDougall JA, Banegas MP, Wiggins CL, Chiu VK, Rajput A, Kinney AY (2018) Rural Disparities in Treatment-Related Financial Hardship and Adherence to Surveillance Colonoscopy in Diverse Colorectal Cancer Survivors. Cancer Epidemiol Biomarkers Prev 27(11):1275–1282. https://doi.org/10.1158/1055-9965.Epi-17-1083
McDougall JA, Blair CK, Wiggins CL, Goodwin MB, Chiu VK, Rajput A et al (2019) Socioeconomic disparities in health-related quality of life among colorectal cancer survivors. J Cancer Surviv 13(3):459–467. https://doi.org/10.1007/s11764-019-00767-9
Blair CK, McDougall JA, Chiu VK, Wiggins CL, Rajput A, Harding EM et al (2019) Correlates of poor adherence to a healthy lifestyle among a diverse group of colorectal cancer survivors. Cancer Causes Control 30(12):1327–1339. https://doi.org/10.1007/s10552-019-01241-8
Hart LG, Larson EH, Lishner DM (2005) Rural definitions for health policy and research. Am J Public Health 95(7):1149–1155. https://doi.org/10.2105/ajph.2004.042432
Chew LD, Griffin JM, Partin MR, Noorbaloochi S, Grill JP, Snyder A et al (2008) Validation of screening questions for limited health literacy in a large VA outpatient population. J Gen Intern Med 23(5):561–566. https://doi.org/10.1007/s11606-008-0520-5
Chew LD, Bradley KA, Boyko EJ (2004) Brief questions to identify patients with inadequate health literacy. Fam Med 36(8):588–594
Schlesinger S, Walter J, Hampe J, von Schönfels W, Hinz S, Küchler T et al (2014) Lifestyle factors and health-related quality of life in colorectal cancer survivors. Cancer Causes Control 25(1):99–110. https://doi.org/10.1007/s10552-013-0313-y
Centers for Disease Control and Prevention (2015) Defining Adult Overweight and Obesity. https://www.cdc.gov/obesity/adult/defining.html. Accessed 5 April 2017
McCaul KD and Goetz P. In: NIH Division of Cancer Control & Population Sciences, Behavioral Research Program. Constructs and Measures of Health Behavior: Worry. https://cancercontrol.cancer.gov/brp/research/constructs/worry.html. Last updated Sept 2020
Glanz K, Grove J, Le Marchand L, Gotay C (1999) Underreporting of family history of colon cancer: correlates and implications. Cancer Epidemiol Biomarkers Prev 8(7):635–639
Mullens AB, McCaul KD, Erickson SC, Sandgren AK (2004) Coping after cancer: risk perceptions, worry, and health behaviors among colorectal cancer survivors. Psychooncology 13(6):367–376. https://doi.org/10.1002/pon.751
Holland JC, Andersen B, Breitbart WS, Buchmann LO, Compas B, Deshields TL et al (2013) Distress management. J Natl Compr Canc Netw 11(2):190–209
Anderson RJ, Freedland KE, Clouse RE, Lustman PJ (2001) The prevalence of comorbid depression in adults with diabetes. Diabetes Care 24(6):1069–1078
Chan AT, Ogino S, Fuchs CS (2009) Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302(6):649–658
Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M et al (2012) Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 367(17):1596–1606
Rothwell PM, Wilson M, Price JF, Belch JFF, Meade TW, Mehta Z (2012) Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. The Lancet 379(9826):1591–1601. https://doi.org/10.1016/S0140-6736(12)60209-8
Hawkins ML, Buys SS, Gren LH, Simonsen SE, Kirchhoff AC, Hashibe M (2017) Do cancer survivors develop healthier lifestyle behaviors than the cancer-free population in the PLCO study? J Cancer Surviv 11(2):233–245
Gupta S, Cole AP, Marchese M, Wang Y, Speed JM, Fletcher SA et al 2018 Use of Preventive Health Services Among Cancer Survivors in the U.S. American Journal of Preventive Medicine. 55(6):830–8. https://doi.org/10.1016/j.amepre.2018.07.021.
Zanders MMJ, van Herk-Sukel MPP, Vissers PAJ, Herings RMC, Haak HR, van de Poll-Franse LV (2015) Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another? Br J Cancer 113(3):403–410. https://doi.org/10.1038/bjc.2015.259
Hua X, Phipps AI, Burnett-Hartman AN, Adams SV, Hardikar S, Cohen SA et al (2017) Timing of Aspirin and Other Nonsteroidal Anti-Inflammatory Drug Use Among Patients With Colorectal Cancer in Relation to Tumor Markers and Survival. J Clin Oncol 35(24):2806–2813. https://doi.org/10.1200/jco.2017.72.3569
Sanchez DR, Diez Roux AV, Michos ED, Blumenthal RS, Schreiner PJ, Burke GL et al (2011) Comparison of the racial/ethnic prevalence of regular aspirin use for the primary prevention of coronary heart disease from the multi-ethnic study of atherosclerosis. Am J Cardiol 107(1):41–46. https://doi.org/10.1016/j.amjcard.2010.08.041
Brown DW, Shepard D, Giles WH, Greenlund KJ, Croft JB (2005) Racial differences in the use of aspirin: an important tool for preventing heart disease and stroke. Ethn Dis 15(4):620–626
Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med. 2006;30(1):74–7. https://doi.org/10.1016/j.amepre.2005.08.042.
Qato DM, Lindau ST, Conti RM, Schumm LP, Alexander GC (2010) Racial and ethnic disparities in cardiovascular medication use among older adults in the United States. Pharmacoepidemiol Drug Saf 19(8):834–842. https://doi.org/10.1002/pds.1974
Misialek JR, Van’t Hof JR, Oldenburg NC, Jones C, Eder M, Luepker RV et al. Aspirin Use and Awareness for Cardiovascular Disease Prevention Among Hispanics: Prevalence and Associations with Health Behavior Beliefs. Journal of Community Health. 2020:1–8.
Raber I, McCarthy CP, Vaduganathan M, Bhatt DL, Wood DA, Cleland JGF et al (2019) The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet 393(10186):2155–2167. https://doi.org/10.1016/s0140-6736(19)30541-0
Anderson AE, Flores KG, Boonyasiriwat W, Gammon A, Kohlmann W, Birmingham WC et al (2014) Interest and informational preferences regarding genomic testing for modest increases in colorectal cancer risk. Public Health Genomics 17(1):48–60. https://doi.org/10.1159/000356567
El-Haddad B, Dong F, Kallail KJ, Hines RB, Ablah E (2015) Association of marital status and colorectal cancer screening participation in the USA. Colorectal Dis 17(5):O108–O114. https://doi.org/10.1111/codi.12926
Leventhal KG, Tuong W, Peshkin BN, Salehizadeh Y, Fishman MB, Eggly S et al (2013) “Is it really worth it to get tested?”: primary care patients’ impressions of predictive SNP testing for colon cancer. J Genet Couns 22(1):138–151. https://doi.org/10.1007/s10897-012-9530-x
Evans CN, Brewer NT, Vadaparampil ST, Boisvert M, Ottaviano Y, Lee MC et al (2016) Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy. Breast Cancer Res Treat 156(3):549–555
Mai PL, Vadaparampil ST, Breen N, McNeel TS, Wideroff L, Graubard BI (2014) Awareness of cancer susceptibility genetic testing: the 2000, 2005, and 2010 National Health Interview Surveys. Am J Prev Med 46(5):440–448. https://doi.org/10.1016/j.amepre.2014.01.002
Wolyniec K, Sharp J, Lazarakis S, Mileshkin L, Schofield P (2020) Understanding and information needs of cancer patients regarding treatment-focused genomic testing: A systematic review. Psychooncology 29(4):632–638
Naik H, Qiu X, Brown M, Eng L, Pringle D, Mahler M et al (2016) Socioeconomic status and lifestyle behaviours in cancer survivors: smoking and physical activity. Current Oncology 23(6)
Olfson E, Hartz S, Carere DA, Green RC, Roberts JS, Bierut LJ et al (2016) Implications of Personal Genomic Testing for Health Behaviors: The Case of Smoking. Nicotine Tob Res 18(12):2273–2277. https://doi.org/10.1093/ntr/ntw168
Smits SE, McCutchan GM, Hanson JA, Brain KE (2018) Attitudes towards lung cancer screening in a population sample. Health Expect 21(6):1150–1158
Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW, García FA et al (2016) Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA 315(23):2564–2575
Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J et al (2018) Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med 379(16):1529–1539. https://doi.org/10.1056/NEJMoa1804988
Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB et al (2018) Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 392(10152):1036–1046. https://doi.org/10.1016/s0140-6736(18)31924-x
McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR et al (2018) Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med 379(16):1509–1518. https://doi.org/10.1056/NEJMoa1805819
Mahmoud AN, Gad MM, Elgendy AY, Elgendy IY, Bavry AA (2018) Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur Heart J 40(7):607–617. https://doi.org/10.1093/eurheartj/ehy813
Shi Q, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J et al 2017 Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. Journal of Clinical Oncology. 35(18_suppl):LBA1-LBA. https://doi.org/10.1200/JCO.2017.35.18_suppl.LBA1.
Ali R, Toh HC, Chia WK (2011) The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer–the ASCOLT study: study protocol for a randomized controlled trial. Trials 12:261. https://doi.org/10.1186/1745-6215-12-261
Sankaranarayanan R, Kumar DR, Altinoz MA, Bhat GJ (2020) Mechanisms of Colorectal Cancer Prevention by Aspirin-A Literature Review and Perspective on the Role of COX-Dependent and -Independent Pathways. Int J Mol Sci 21(23). https://doi.org/10.3390/ijms21239018
Aimo A, De Caterina R (2019) Aspirin for primary cardiovascular prevention: is there a need for risk stratification? Eur Heart J 40(34):2922–2923. https://doi.org/10.1093/eurheartj/ehz223
Boakye D, Rillmann B, Walter V, Jansen L, Hoffmeister M, Brenner H (2018) Impact of comorbidity and frailty on prognosis in colorectal cancer patients: A systematic review and meta-analysis. Cancer Treat Rev 64:30–39. https://doi.org/10.1016/j.ctrv.2018.02.003
Jiang Y, Ben Q, Shen H, Lu W, Zhang Y, Zhu J (2011) Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol 26(11):863–876. https://doi.org/10.1007/s10654-011-9617-y
Mills KT, Bellows CF, Hoffman AE, Kelly TN, Gagliardi G (2013) Diabetes mellitus and colorectal cancer prognosis: A meta-analysis. Dis Colon Rectum 56(11):1304–1319. https://doi.org/10.1097/DCR.0b013e3182a479f9
Croft B, Reed M, Patrick C, Kovacevich N, Voutsadakis IA (2019) Diabetes, Obesity, and the Metabolic Syndrome as Prognostic Factors in Stages I to III Colorectal Cancer Patients. J Gastrointest Cancer 50(2):221–229. https://doi.org/10.1007/s12029-018-0056-9
Dillman DA. Mail and Internet surveys: The tailored design method--2007 Update with new Internet, visual, and mixed-mode guide. John Wiley & Sons; 2011.
Chawla N, Blanch-Hartigan D, Virgo KS, Ekwueme DU, Han X, Forsythe L et al (2016) Quality of Patient-Provider Communication Among Cancer Survivors: Findings From a Nationally Representative Sample. J Oncol Practice 12(12):e964–e973. https://doi.org/10.1200/jop.2015.006999
Funding
This research was funded by Carolyn R. Surface Foundation and University of New Mexico Comprehensive Cancer Center (NCI P30CA118100). Dr. Denalee O’Malley was supported by 1K99CA256043-01.Dr. Cindy Blair was supported by K07CA215937.
The study was reviewed and approved by the Human Research Protections Office of the University of New Mexico Health Sciences Center (Federal Wide Assurance #00003255). All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Drs. Denalee O’Malley, Cindy Blair, Alissa Greenbaum, Charles Wiggins, Ashwani Rajput, Vi Chiu, and Anita Kinney declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
O’Malley, D.M., Blair, C.K., Greenbaum, A. et al. Colorectal Cancer Survivors’ Receptivity toward Genomic Testing and Targeted Use of Non-Steroidal Anti-Inflammatory Drugs to Prevent Cancer Recurrence. J Community Genet 13, 201–214 (2022). https://doi.org/10.1007/s12687-021-00574-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12687-021-00574-9